Marshall Fordyce, M.D.
Principal executive officer pay for Marshall Fordyce, M.D., by year and company, from pay-versus-performance disclosure. Every figure links to its source on the company page.
Vera Therapeutics, Inc. (VERA) FY2023–FY2025
Beat peersTSR 229% vs peer group 31% over FY2023–FY2025
Turnaround$100 invested moved from behind the peer group ($79.48 vs $104.70) to ahead ($261.70 vs $136.72) over FY2023–FY2025
Aligned: paid up as stock roseCAP $1,986,784→$9,126,943 while $100 invested went $79.48→$261.70
| Fiscal year | SCT total | Comp actually paid |
|---|---|---|
| FY2023 | $3.4M | $2.0M |
| FY2024 | $5.6M | $31.2M |
| FY2025 | $7.0M | $9.1M |
The company's "$100 invested" index ran $79.48 at FY2023 → $261.70 by FY2025 — an annualized return of 81.5%.
Track record
1 measurable tenure in the pay-versus-performance disclosure window. Best annualized TSR: 81.5%/yr at VERA ( FY2023–FY2025). See the CEO track-record ranking for context.